Skip to main content

Roivant Sciences Ltd.

For the period ended Mar 31, 2025. Filed May 29, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed May 29, 2025

ROIV$40.67+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 9B. Other Information

ITEM 9B.OTHER INFORMATION

On March 28, 2025, Eric Venker, RSI’s President and Chief Operating Officer, entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential sale of up to 3,842,209 common shares held by Mr. Venker between October 6, 2025 and October 13, 2026.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.